

APRIL 2017 PBAC MEETING – POSITIVE RECOMMENDATION

| DRUG, SPONSOR, TYPE OF SUBMISSION | DRUG TYPE OR USE | LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION | PBAC OUTCOME |
|---|--|--|---|
| <p>VEMURAFENIB (monotherapy)</p> <p>Tablet 240 mg</p> <p>Zelboraf®</p> <p>Roche Products Pty Ltd</p> <p>New listing</p> | <p>Unresectable Stage III or Stage IV malignant melanoma</p> | <p>To request the PBS listing of vemurafenib monotherapy for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma.</p> | <p>The PBAC recommended the listing of vemurafenib monotherapy for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or Stage IV malignant melanoma as an authority required (streamlined) listing in the General Schedule on a cost-minimisation basis with dabrafenib.</p> <p>The PBAC recommended that the restriction should be the same as the restriction for dabrafenib monotherapy for unresectable Stage III or Stage IV malignant melanoma.</p> |